<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties open-access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6427931</article-id><article-id pub-id-type="pmid">30865617</article-id><article-id pub-id-type="doi">10.12659/MSM.913057</article-id><article-id pub-id-type="publisher-id">913057</article-id><article-categories><subj-group subj-group-type="heading"><subject>Molecular Biology</subject></subj-group></article-categories><title-group><article-title>Both Peripheral Blood and Urinary miR-195-5p, miR-192-3p, miR-328-5p and Their Target Genes PPM1A, RAB1A and BRSK1 May Be Potential Biomarkers for Membranous Nephropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Guangyu</given-names></name><xref ref-type="aff" rid="af1-medscimonit-25-1903">1</xref><xref ref-type="author-notes" rid="fn1-medscimonit-25-1903">A</xref><xref ref-type="author-notes" rid="fn5-medscimonit-25-1903">E</xref><xref ref-type="author-notes" rid="fn7-medscimonit-25-1903">G</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiaofei</given-names></name><xref ref-type="aff" rid="af2-medscimonit-25-1903">2</xref><xref ref-type="author-notes" rid="fn2-medscimonit-25-1903">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-25-1903">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-25-1903">D</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wanning</given-names></name><xref ref-type="aff" rid="af3-medscimonit-25-1903">3</xref><xref ref-type="author-notes" rid="fn4-medscimonit-25-1903">D</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wenlong</given-names></name><xref ref-type="aff" rid="af4-medscimonit-25-1903">4</xref><xref ref-type="author-notes" rid="fn3-medscimonit-25-1903">C</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Huaying</given-names></name><xref ref-type="aff" rid="af1-medscimonit-25-1903">1</xref><xref ref-type="author-notes" rid="fn2-medscimonit-25-1903">B</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xin</surname><given-names>Guangda</given-names></name><xref ref-type="aff" rid="af1-medscimonit-25-1903">1</xref><xref ref-type="author-notes" rid="fn1-medscimonit-25-1903">A</xref><xref ref-type="author-notes" rid="fn5-medscimonit-25-1903">E</xref></contrib></contrib-group><aff id="af1-medscimonit-25-1903">
<label>1</label>Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, P.R. China</aff><aff id="af2-medscimonit-25-1903">
<label>2</label>Department of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, P.R. China</aff><aff id="af3-medscimonit-25-1903">
<label>3</label>Department of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, P.R. China</aff><aff id="af4-medscimonit-25-1903">
<label>4</label>Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, P.R. China</aff><author-notes><corresp id="c1-medscimonit-25-1903">Corresponding Author: Guangda Xin, e-mail: <email>guangdaxin2018@163.com</email></corresp><fn id="fn1-medscimonit-25-1903"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-25-1903"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-25-1903"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-25-1903"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-25-1903"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-25-1903"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-25-1903"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>13</day><month>3</month><year>2019</year></pub-date><volume>25</volume><fpage>1903</fpage><lpage>1916</lpage><history><date date-type="received"><day>04</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>05</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>&#169; Med Sci Monit, 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>)</license-p></license></permissions><abstract><sec><title>Background</title><p>To identify noninvasive diagnostic biomarkers for membranous nephropathy (MN).</p></sec><sec><title>Material/Methods</title><p>The mRNA microarray datasets GSE73953 using peripheral blood mononuclear cells (PBMCs) of 8 membranous nephropathy patients and 2 control patients; and microRNAs (miRNA) microarray dataset GSE64306 using urine sediments of 4 membranous nephropathy patients and 6 control patients were downloaded from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were respectively identified from PBMCs and urine sediments of membranous nephropathy patients, followed with functional enrichment analysis, protein-protein interaction (PPI) analysis, and miRNA-target gene analysis. Finally, the DEGs and the target genes of DEMs were overlapped to obtain crucial miRNA-mRNA interaction pairs for membranous nephropathy.</p></sec><sec><title>Results</title><p>A total of 1246 DEGs were identified from PBMCs samples, among them upregulated CCL5 was found to be involved in the chemokine signaling pathway, and BAX was found to be apoptosis related; while downregulated PPM1A and CDK1 were associated with the MAPK signaling pathway and the p53 signaling pathway, respectively. The hub role of CDK1 (degree=18) and CCL5 (degree=12) were confirmed after protein-protein interaction network analysis in which CKD1 could interact with RAB1A. A total of 28 DEMs were identified in urine sediments. The 276 target genes of DEMs were involved in cell cycle arrest (PPM1A) and intracellular signal transduction (BRSK1). Thirteen genes were shared between the DEGs in PMBCs and the target genes of DEMs in urine sediments, but only hsa-miR-192-3p-RAB1A, hsa-miR-195-5p-PPM1A, and hsa-miR-328-5p-BRSK1 were negatively related in their expression level.</p></sec><sec><title>Conclusions</title><p>Both peripheral blood and urinary miR-195-5p, miR-192-3p, miR-328-5p, and their target genes PPM1A, RAB1A, and BRSK1 may be potential biomarkers for membranous nephropathy by participating in inflammation and apoptosis.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Apoptosis</kwd><kwd>Biological Markers</kwd><kwd>Glomerulonephritis, Membranous</kwd><kwd>Inflammation Mediators</kwd><kwd>MicroRNAs</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Membranous nephropathy (MN) is one of the commonly diagnosed kidney diseases, with the incidence rate increased by more than 2 times from 2003 to 2014 in China [<xref rid="b1-medscimonit-25-1903" ref-type="bibr">1</xref>]. It is estimated that approximately 20% of patients with MN will progress to end stage renal disease and 10% of them will die within 5 to 10 years [<xref rid="b2-medscimonit-25-1903" ref-type="bibr">2</xref>,<xref rid="b3-medscimonit-25-1903" ref-type="bibr">3</xref>]. Thus, accurate and timely diagnosis is required to prevent possible progression and improve patient outcomes.</p><p>Currently, renal biopsy and histological evaluation remain as the standard procedure for diagnosis of MN. However, renal biopsy is invasive, which may cause some unanticipated complications in the patients at high risk [<xref rid="b4-medscimonit-25-1903" ref-type="bibr">4</xref>,<xref rid="b5-medscimonit-25-1903" ref-type="bibr">5</xref>]. Hence, there is an urgent need to identify some noninvasive diagnostic biomarkers for MN.</p><p>The majority of MN is idiopathic (IMN) and the remainder is secondary to systemic autoimmune disease, certain malignancies, infections, or exposure to environmental factors [<xref rid="b6-medscimonit-25-1903" ref-type="bibr">6</xref>]. Previous studies have shown that circulating autoantibodies against the M-type phospholipase A2 receptor (anti-PLA2R) are detectable in 80% of IMN patients and thus serum anti-PLA2R has been widely accepted as a biomarker for clinical diagnosis of IMN [<xref rid="b7-medscimonit-25-1903" ref-type="bibr">7</xref>]. The coincidence rate of serum anti-PLA2R antibody and PLA2R in kidney tissue has been demonstrated to be 100% [<xref rid="b8-medscimonit-25-1903" ref-type="bibr">8</xref>]. The remainder of MN cases may be associated with the inflammatory state [<xref rid="b9-medscimonit-25-1903" ref-type="bibr">9</xref>] and therefore several circulatory immune cells and inflammatory cytokines have also been suggested as biomarkers for secondary MN. For example, Zhang et al. detected that concentrations of serum interleukin (IL)-2, IL-4, IL-10, IL-17A, and interferon (IFN)-&#947; were higher in the MN patients compared to controls [<xref rid="b10-medscimonit-25-1903" ref-type="bibr">10</xref>]. Liu et al. observed the percentages of CD38(+) CD19(+), IL-10(+) CD19(+) B cells, and serum IL-10 level in MN patients were significantly higher than in health controls. The percentage of CD38(+) CD19(+) was positively correlated with the 24-hour urine protein concentration and negatively correlated with the value of estimated glomerular filtration rate (eGFR), which was the opposite with IL-10(+) CD19(+) B cells and serum IL-10 level [<xref rid="b11-medscimonit-25-1903" ref-type="bibr">11</xref>]. Nagasawa et al. [<xref rid="b12-medscimonit-25-1903" ref-type="bibr">12</xref>] used DNA microarray analysis to search peripheral blood mononuclear cells (PBMCs) mRNA for genes that had expression levels that distinguished between patients with MN and healthy volunteers. They proposed that IFN-alpha-inducible protein 27 in the peripheral blood could serve as a noninvasive marker for MN diagnosis. However, the clinical applications remain rare and further studies are still needed to investigate novel biomarkers for MN.</p><p>MicroRNAs (miRNAs) are a class of small noncoding RNA that negatively regulate gene expression by translational repression or induction of messenger RNA degradation. Recently, miRNAs have been found to be implicated in the development of nephropathy by influencing the inflammatory related genes [<xref rid="b13-medscimonit-25-1903" ref-type="bibr">13</xref>,<xref rid="b14-medscimonit-25-1903" ref-type="bibr">14</xref>] and thus they may also be underlying biomarkers for MN. This hypothesis was demonstrated in the study of Li et al. that found miR-217 regulated the expression of TNF superfamily member 11 (TNFSF11). Compared with control patients, miR-217 was significantly downregulated and TNFSF11 was significantly upregulated in MN patients. The patients with MN and the control patients could then be obviously separated according to the expression of miR-217, with an area under the curve of 0.941, and sensitivity and specificity of 88.9% and 75.9% respectively [<xref rid="b13-medscimonit-25-1903" ref-type="bibr">13</xref>]. However, miRNA biomarkers for diagnosis of MN remain rarely reported [<xref rid="b15-medscimonit-25-1903" ref-type="bibr">15</xref>].</p><p>The goal of this study was to further screen inflammatory related miRNA-mRNA biomarkers in both blood and urine samples for MN by using the microarray datasets downloaded from a public database. The miRNA-mRNA interaction and their function were also investigated. Our study may provide more noninvasive diagnostic biomarkers for MN.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec sec-type="methods"><title>Data collection</title><p>The mRNA microarray data under accession number GSE73953 contributed by Nagasawa et al. [<xref rid="b12-medscimonit-25-1903" ref-type="bibr">12</xref>] was downloaded from the Gene Expression Omnibus (GEO) repository at the National Center for Biotechnology Information (NCBI) (<italic><ext-link ext-link-type="uri" xlink:href="www.ncbi.nlm.nih.gov/geo">www.ncbi.nlm.nih.gov/geo</ext-link></italic>) based on the platform of GPL4133 Agilent-014850 Whole Human Genome Microarray 4x44K G4112F. This dataset consisted of 25 PBMCs samples from 8 MN patients and 2 pooled healthy participants.</p><p>The miRNA expression profile under accession number GSE64306 deposited by Wang et al. [<xref rid="b16-medscimonit-25-1903" ref-type="bibr">16</xref>] was also downloaded from GEO on the basis of the platform of GPL19117 [miRNA-4] Affymetrix Multispecies miRNA-4 Array. The miRNA expression analysis was performed in urine sediments from 4 MN patients and 6 healthy participants.</p></sec><sec sec-type="methods"><title>Data preprocessing and differential expression analysis</title><p>The raw CEL files were preprocessed and normalized using the Robust Multichip Average (RMA) algorithm [<xref rid="b17-medscimonit-25-1903" ref-type="bibr">17</xref>] in the R Bioconductor affy package (version 3.4.1; <italic><ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/packages/release/bioc/html/affy.html">http://www.bioconductor.org/packages/release/bioc/html/affy.html</ext-link></italic>). The differentially expressed genes (DEGs) and the differentially expressed miRNAs (DEMs) between MN patients and controls were screened using the linear models for microarray data (LIMMA) method [<xref rid="b18-medscimonit-25-1903" ref-type="bibr">18</xref>] in the Bioconductor R package (version 3.34.0; <italic><ext-link ext-link-type="uri" xlink:href="http://www.bioconductor.org/packages/release/bioc/html/limma.html">http://www.bioconductor.org/packages/release/bioc/html/limma.html</ext-link></italic>). The |log fold change (FC)| &gt;1 and <italic>P</italic>&lt;0.05 were set as the threshold values. A heatmap was created using R package pheatmap (version: 1.0.8; <italic><ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/web/packages/pheatmap/index.html">http://cran.r-project.org/web/packages/pheatmap/index.html</ext-link></italic>) [<xref rid="b19-medscimonit-25-1903" ref-type="bibr">19</xref>] to observe whether the use of DEGs and DEMs could distinguish the MN patients from the controls.</p></sec><sec><title>PPI network and module analyses</title><p>Protein-protein interaction (PPI) pairs were predicted by the Search Tool for the Retrieval of Interacting Genes (STRING, version 10.0; <italic><ext-link ext-link-type="uri" xlink:href="http://www.string-db.org/">http://www.string-db.org/</ext-link></italic>) [<xref rid="b20-medscimonit-25-1903" ref-type="bibr">20</xref>]. Then, the PPI network of DEGs was constructed using Cytoscape software (version 3.4; <italic><ext-link ext-link-type="uri" xlink:href="www.cytoscape.org/">www.cytoscape.org/</ext-link></italic>) [<xref rid="b21-medscimonit-25-1903" ref-type="bibr">21</xref>] based on the obtained PPI pairs. In the PPI network, the node score was calculated based on degree centrality. The node with the high score, which likely played an important role in the PPI network, was referred to as the hub protein. Following PPI network analysis, the significant modules were identified from the PPI network using the Molecular Complex Detection (MCODE; version 1.4.2, <italic><ext-link ext-link-type="uri" xlink:href="http://apps.cytoscape.org/apps/mcode">http://apps.cytoscape.org/apps/mcode</ext-link></italic>) [<xref rid="b22-medscimonit-25-1903" ref-type="bibr">22</xref>] plugin in the Cytoscape software [<xref rid="b21-medscimonit-25-1903" ref-type="bibr">21</xref>] with degree cutoff &#8805;2 and k-core &#8805;3.</p></sec><sec sec-type="methods"><title>miRNA-target gene regulatory analysis</title><p>The target genes of DEMs were predicted using an online resource, miRDB (version 1.0; <italic><ext-link ext-link-type="uri" xlink:href="http://mirdb.org">http://mirdb.org</ext-link></italic>) [<xref rid="b23-medscimonit-25-1903" ref-type="bibr">23</xref>]. Subsequently, the DEMs-target gene regulatory network was also constructed using Cytoscape software [<xref rid="b21-medscimonit-25-1903" ref-type="bibr">21</xref>]. The DEGs identified in GSE73953 and the target genes of DEMs identified in GSE64306 were integrated to obtain the intersection genes between PBMCs and urine sediments samples.</p></sec><sec><title>Functional enrichment analyses</title><p>Gene Ontology (GO) biological process [<xref rid="b24-medscimonit-25-1903" ref-type="bibr">24</xref>] and the Kyoto Encyclopedia of Genes Genomes (KEGG) [<xref rid="b25-medscimonit-25-1903" ref-type="bibr">25</xref>] pathway enrichment analyses were carried out for all identified DEGs, the DEGs in modules, and the target genes of DEMs using the Database for Annotation, Visualization and Integrated Discovery (DAVID, version 6.8; <italic><ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/">http://david.abcc.ncifcrf.gov/</ext-link></italic>) [<xref rid="b26-medscimonit-25-1903" ref-type="bibr">26</xref>] tool. A <italic>P</italic> value &lt;0.05 was selected as the threshold value.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>DEGs identification in PMBCs samples</title><p>After normalization, a total of 1246 DEGs were identified from PMBCs samples of MN patients compared with controls based on the thresholds of |logFC| &gt;1 and <italic>P</italic>&lt;0.05, including 643 upregulated (BRSK1, BR serine/threonine kinase 1; RFX7, regulatory factor X7; CNOT6L, CCR4-NOT transcription complex subunit 6 like; FBXO32, F-box protein 32; ZNF800, zinc finger protein 800; ZNF532, zinc finger protein 532; MBNL3, muscle blind like splicing regulator 3; CCL5, C-C motif chemokine ligand 5; MAPK11, mitogen-activated protein kinase 11; MAPK15) and 603 downregulated genes (PPM1A, protein phosphatase, Mg2+/Mn2+ dependent 1A; CDK1, cyclin dependent kinase 1; RAB1A, RAB1A, member RAS oncogene family; SEC24C, SEC24 homolog C, COPII coat complex component; PCMT1, protein-L-isoaspartate (D-aspartate) O-methyltransferase; AKTIP, AKT interacting protein; SLC13A3, solute carrier family 13 member 3) (<xref rid="t1-medscimonit-25-1903" ref-type="table">Table 1</xref>). Heat map analysis showed that the MN and control groups were well distinguished by the DEGs (<xref ref-type="fig" rid="f1-medscimonit-25-1903">Figure 1A</xref>).</p></sec><sec><title>Functional enrichment analyses for DEGs in PMBCs samples</title><p>The upregulated DEGs were significantly enriched into 10 KEGG pathways (including Prion diseases, CCL5) and 43 GO biological process terms (including negative regulation of neuron apoptotic process, BAX), while the downregulated DEGs were significantly enriched into 12 KEGG pathways (including hsa04010: MAPK signaling pathway, PPM1A; hsa04115: p53 signaling pathway, CDK1), and 20 GO biological process terms (<xref rid="t2-medscimonit-25-1903" ref-type="table">Table 2</xref>).</p></sec><sec><title>PPI network and module analyses for DEGs in PMBCs samples</title><p>A total of 621 PPI pairs (i.e., CDK1-RAB1A), were predicted from the DEGs, which were then used for constructing the PPI network, including 329 nodes (<xref ref-type="fig" rid="f2-medscimonit-25-1903">Figure 2</xref>). The hub proteins in the PPI network were screened by calculating the degree. The results (<xref ref-type="fig" rid="f3-medscimonit-25-1903">Figure 3</xref>) showed CDK1 (degree=18), CCL5 (degree=12), and MAPK11 (degree=8) may be crucial genes for MN.</p><p>From the PPI network, 3 significant modules were screened (<xref ref-type="fig" rid="f4-medscimonit-25-1903">Figure 4</xref>). Functional enrichment analyses revealed that the genes in module 2 were involved in hsa04062: chemokine signaling pathway (CCL5) and hsa04060: cytokine-cytokine receptor interaction (CCL5) (<xref rid="t3-medscimonit-25-1903" ref-type="table">Table 3</xref>).</p></sec><sec><title>DEMs identification</title><p>A total of 28 DEMs, including 21 upregulated (including hsa-miR-214-3p, hsa-miR-192-3p, hsa-miR-20a-5p, and hsa-miR-195-5p) and 7 downregulated miRNAs (including hsa-miR-328-5p), were identified between urine sediments of MN patients and controls (<xref rid="t1-medscimonit-25-1903" ref-type="table">Table 1</xref>). Heat map analysis showed that the MN group and the control group were also well distinguished by the DEMs (<xref ref-type="fig" rid="f1-medscimonit-25-1903">Figure 1B</xref>).</p></sec><sec sec-type="methods"><title>miRNA-target gene regulatory network analysis for DEMs</title><p>Using the miRDB database, 276 target genes of DEMs were predicted. The DEMs-target gene regulatory network was constructed as shown in <xref ref-type="fig" rid="f5-medscimonit-25-1903">Figure 5</xref>, with the miR-30e-5p, miR-195-5p, and miR-20a-5p regulating more target genes.</p></sec><sec><title>Functional enrichment analyses for DEMs</title><p>The functions of the target genes of DEMs were predicted by GO and KEGG enrichment analyses using DAVID. As shown in <xref rid="t4-medscimonit-25-1903" ref-type="table">Table 4</xref>, these target genes were significantly enriched in 26 GO terms, such as cell cycle arrest (PPM1A), intracellular signal transduction (BRSK1), protein phosphorylation (BRSK1), and establishment of cell polarity (BRSK1).</p></sec><sec sec-type="methods"><title>Integrated analysis of 2 datasets</title><p>A total of 13 intersection genes were identified between DEGs in PMBCs and the target genes of DEMs in urine sediments, such as RFX7, MBNL3, SEC24C, FBXO32, ZNF800, ZNF532, RAB1A, AKTIP, SLC13A3, PPM1A, CNOT6L, PCMT1, and BRSK1 (<xref rid="t5-medscimonit-25-1903" ref-type="table">Table 5</xref>). Among them, hsa-miR-214-3p-SEC24C, hsa-miR-192-3p (upregulated)-RAB1A (downregulated), hsa-miR-20a-5p (upregulated)-AKTIP (downregulated), hsa-miR-195-5p (upregulated)-SLC13A3 (downregulated), hsa-miR-195-5p (upregulated)-PPM1A (downregulated), and hsa-miR-328-5p (downregulated)-BRSK1 (upregulated) were negatively related in their expression level (<xref rid="t1-medscimonit-25-1903" ref-type="table">Table 1</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>By integrating the mRNA expression profile data in PBMCs and miRNA expression profile data in urine sediments, our present study suggests that hsa-miR-195-5p, hsa-miR-192-3p, hsa-miR-328-5p, and their target genes PPM1A, RAB1A, and BRSK1 may be crucial biomarkers for the diagnosis and development of MN. PPM1A and BRSK1 may be involved in MN by participating in the MAPK related signaling pathway, while RAB1A may also be associated with MN by involving the p53 signaling pathway (CDK1-RAB1A).</p><p>Accumulating evidence has demonstrated that the MAPK pathway is frequently activated in nephropathy. Activated p38 MAPK mediates apoptosis of glomerular podocytes by increasing the Bax/Bcl-2 ratio [<xref rid="b27-medscimonit-25-1903" ref-type="bibr">27</xref>,<xref rid="b28-medscimonit-25-1903" ref-type="bibr">28</xref>]. Furthermore, activated extracellular signal-regulated kinase (ERK1/2) and p38 MAPK were also reported to induce an increase in the activity of nuclear factor-kappaB (NF-&#954;B) and produce the expression of several pro-inflammatory cytokines, such as IL-6, IL-1, tumor necrosis factor (TNF)-alpha, and IL-17, resulting in renal injury, which could be reversed by their inhibitors [<xref rid="b29-medscimonit-25-1903" ref-type="bibr">29</xref>,<xref rid="b30-medscimonit-25-1903" ref-type="bibr">30</xref>]. Thus, inhibition of the MAPK signaling pathway has been suggested as an underlying treatment approach for nephropathy. This hypothesis has been investigated in several studies. For example, Zheng et al. demonstrated astragaloside IV restored podocyte morphology and cytoskeleton loss induced by complement membranous attack complex by reducing the phosphorylation of JNK and ERK1/2 and attenuated podocyte injury in MN [<xref rid="b31-medscimonit-25-1903" ref-type="bibr">31</xref>]. Malik et al. observed the use of apigenin ameliorated streptozotocin-induced diabetic nephropathy in rats via preventing the activation of the MAPK pathway, which then inhibited inflammation (reduced TNF-&#945;, IL-6, and NF-&#954;B expression) and apoptosis (increased expression of Bcl-2 and decreased Bax and caspase-3) [<xref rid="b32-medscimonit-25-1903" ref-type="bibr">32</xref>]. Similarly, pretreatment with galangin preserved renal function (normalized serum creatinine and blood urea nitrogen), suppressed oxidative stress (decreased level of malondialdehyde), inflammation (reduced levels of TNF-&#945; and IL-6), and the activation of apoptotic pathways (decreased expression of Bax and caspase-3) by de-phosphorylating p38, JNK, and ERK1/2 proteins [<xref rid="b33-medscimonit-25-1903" ref-type="bibr">33</xref>]. In our study, MAPK11, MAPK15 as well as pro-inflammatory cytokine CCL5 and pro-apoptotic Bax were also found to be significantly upregulated in MN, further verifying the MAPK-mediated inflammation and apoptosis mechanisms for MN. In addition, a recent study found that PPM1A could negatively regulate ERK by directly dephosphorylating its pT position early in epidermal growth factor stimulation [<xref rid="b34-medscimonit-25-1903" ref-type="bibr">34</xref>]. Using a functional genomic approach, PPM1A was shown to dephosphorylate IKK&#946; at Ser177 and Ser181 and terminate IKK&#946;-induced NF-&#954;B activation, leading to inflammation suppression [<xref rid="b35-medscimonit-25-1903" ref-type="bibr">35</xref>]. Furthermore, genetic manipulation experiments demonstrated that knockdown of PPM1A expression accelerated the ability of monocytes to differentiate into inflammatory (M1) macrophages and promoted the production of inflammatory cytokines [<xref rid="b36-medscimonit-25-1903" ref-type="bibr">36</xref>]. Thus, PPM1A may be hypothesized to be downregulated and promote the development of MN by MAPK-mediated inflammation and apoptosis, which was preliminarily proved in our study. However, there was no study to confirm the roles of PPM1A in MN, and thus, further experiments are required. Furthermore, the study of Wang et al. revealed that the expression of BRSK1 was decreased in breast cancer cell lines, and treatment of PI3K inhibitor LY294002 could increase BRSK1 expression, implying BRSK1 may function as a cell apoptosis promotor via PI3K-Akt signaling pathway. Generally, there is crosstalk between the MAPK pathway and the PI3K pathways that plays a role in diseases [<xref rid="b37-medscimonit-25-1903" ref-type="bibr">37</xref>]. Therefore, BRSK1 may also be involved in the MAPK pathway as well as other genes (i.e., MAPK6, MAP3K2, and MAP3K1) enriched in protein phosphorylation. As expected, our study showed BRSK1 was upregulated in MN patients and may cause the apoptosis of glomerular podocytes.</p><p>Although the RAB1A gene was not enriched into any pathway or GO term in our study, it could interact with CDK1 as seen from the PPI analysis and hereby we speculate that RAB1A may play important roles in MN by participating in the p53 signaling pathway which was CDK1 enriched. CDK1 encodes a cyclin kinase that associates with cyclin to control cell cycle transition from G1 to S and promote cell proliferation [<xref rid="b38-medscimonit-25-1903" ref-type="bibr">38</xref>]. Thus, CDK1 may be downregulated in nephropathy [<xref rid="b39-medscimonit-25-1903" ref-type="bibr">39</xref>]; this was also demonstrated by our study in the MN group. Due to interaction with CDK1, RAB1A may also be downregulated in MN as our study reported. This suggested finding can be indirectly demonstrated by other recent studies: Liu et al. found RAB1A was significantly lower in aging renal glomerular mesangial cells [<xref rid="b40-medscimonit-25-1903" ref-type="bibr">40</xref>].</p><p>In addition to genes, miRNAs have also been suggested as key biomarkers in MN [<xref rid="b13-medscimonit-25-1903" ref-type="bibr">13</xref>,<xref rid="b15-medscimonit-25-1903" ref-type="bibr">15</xref>,<xref rid="b41-medscimonit-25-1903" ref-type="bibr">41</xref>]. Thus, we also investigated the DEMs in urine sediments of MN patients. In line with the expression in the peripheral blood samples of MN patients [<xref rid="b41-medscimonit-25-1903" ref-type="bibr">41</xref>] and amniotic fluid exosomes from fetuses with congenital hydronephrosis [<xref rid="b42-medscimonit-25-1903" ref-type="bibr">42</xref>], our results also showed miR-195-5p was high expressed in urine sediments of MN patients. Transfection with miR-195 has been reported to reduce the protein levels of BCL2 and contribute to podocyte apoptosis via an increase in caspase-3 [<xref rid="b43-medscimonit-25-1903" ref-type="bibr">43</xref>], while the use of miRNA-195 inhibitor protected mesangial cells from apoptosis and promoted cellular proliferation <italic>in vitro</italic> [<xref rid="b44-medscimonit-25-1903" ref-type="bibr">44</xref>]. In accordance with these findings, our results also suggested miR-195 could negatively regulate PPM1A which was pro-inflammatory and pro-apoptotic when downregulated as we described. However, the relationship between miR-195 and PPM1A has never been validated in <italic>in vitro</italic> or <italic>in vivo</italic> experiments, and thus needs further investigation. Previously, miR-192 has been reported to be a potential biomarker of ischemia-reperfusion-induced kidney injury because of its increased expression in plasma and urine [<xref rid="b45-medscimonit-25-1903" ref-type="bibr">45</xref>,<xref rid="b46-medscimonit-25-1903" ref-type="bibr">46</xref>]. Also, its high expression has been demonstrated to be associated with the activation by p53 [<xref rid="b47-medscimonit-25-1903" ref-type="bibr">47</xref>], while p53 upregulation suppressed the expression of CDK1 [<xref rid="b48-medscimonit-25-1903" ref-type="bibr">48</xref>] and may also block RAB1A. In accordance with these aforementioned studies, we also found hsa-miR-192-3p was upregulated and could negatively regulate the expression of its target gene RAB1A. However, the relationship between miR-192-3p and RAB1A has never been validated in <italic>in vitro</italic> or <italic>in vivo</italic> experiments, and thus needs further investigation. MiR-328-5p was observed to be downregulated in pressure-induced renal fibrosis and it may function by upregulating its target gene CD44 expression [<xref rid="b49-medscimonit-25-1903" ref-type="bibr">49</xref>]. Renal fibrosis is a pathological characteristic of advanced MN and therefore miR-328-5p may also be downregulated in MN, which was shown to be the case in our study. There have been no studies that have indicated a negative relationship between miR-328 and BRSK1 in MN, which was thus a novel result in our study.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Our study revealed that miR-195-5p, miR-192-3p, miR-328-5p, and their target genes PPM1A, RAB1A, and BRSK1 in peripheral blood and urine samples may be potential biomarkers for MN<italic>.</italic> Further clinical and experimental studies are needed to verify the diagnosis accuracy and interaction mechanism.</p></sec></body><back><fn-group><fn id="fn8-medscimonit-25-1903"><p><bold>Source of support:</bold> This work was supported by the Science and Technology Development Plan Project of Jilin Province (No. 20160101059JC) and the Natural Science Foundation of China (No. 81370810)</p></fn><fn id="fn9-medscimonit-25-1903" fn-type="COI-statement"><p><bold>Conflict of interests</bold></p><p>None.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-25-1903"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>JH</given-names></name><name><surname>Zhu</surname><given-names>HX</given-names></name><name><surname>Zhou</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Changes in the spectrum of kidney diseases: An analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China</article-title><source>Kidney Dis</source><year>2018</year><volume>4</volume><issue>1</issue><fpage>10</fpage><lpage>19</lpage></element-citation></ref><ref id="b2-medscimonit-25-1903"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>JJ</given-names></name><name><surname>Bhandari</surname><given-names>SK</given-names></name><name><surname>Batech</surname><given-names>M</given-names></name><etal/></person-group><article-title>End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population</article-title><source>Mayo Clin Proc</source><year>2018</year><volume>93</volume><issue>2</issue><fpage>167</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">29395351</pub-id></element-citation></ref><ref id="b3-medscimonit-25-1903"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozenberg</surname><given-names>I</given-names></name><name><surname>Kotliroff</surname><given-names>A</given-names></name><name><surname>Zahavi</surname><given-names>T</given-names></name><name><surname>Benchetrit</surname><given-names>S</given-names></name></person-group><article-title>Outcome of idiopathic membranous nephropathy: A retrospective study</article-title><source>Isr Med Assoc J</source><year>2018</year><volume>20</volume><issue>3</issue><fpage>186</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">29527859</pub-id></element-citation></ref><ref id="b4-medscimonit-25-1903"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiro</surname><given-names>M</given-names></name><name><surname>Katoh</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group><article-title>Risk factors for bleeding complications in percutaneous renal biopsy</article-title><source>Clin Exp Nephrol</source><year>2005</year><volume>9</volume><issue>1</issue><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">15830272</pub-id></element-citation></ref><ref id="b5-medscimonit-25-1903"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simardmeilleur</surname><given-names>MC</given-names></name><name><surname>Troyanov</surname><given-names>S</given-names></name><name><surname>Roy</surname><given-names>L</given-names></name><etal/></person-group><article-title>Risk factors and timing of native kidney biopsy complications</article-title><source>Nephron Extra</source><year>2014</year><volume>4</volume><issue>1</issue><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">24803920</pub-id></element-citation></ref><ref id="b6-medscimonit-25-1903"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekula</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Stanescu</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Genetic risk variants for membranous nephropathy: Extension of and association with other chronic kidney disease aetiologies</article-title><source>Nephrol Dial Transplant</source><year>2017</year><volume>32</volume><issue>2</issue><fpage>325</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">27333618</pub-id></element-citation></ref><ref id="b7-medscimonit-25-1903"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name></person-group><article-title>Diagnostic test accuracy of serum anti-PLA2R autoantibodies and glomerular PLA2R antigen for diagnosing idiopathic membranous nephropathy: An updated meta-analysis</article-title><source>Front Med</source><year>2018</year><volume>5</volume><fpage>101</fpage></element-citation></ref><ref id="b8-medscimonit-25-1903"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy</article-title><source>Vasc Health Risk Manag</source><year>2018</year><volume>14</volume><fpage>103</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">29881283</pub-id></element-citation></ref><ref id="b9-medscimonit-25-1903"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawaz</surname><given-names>FA</given-names></name><name><surname>Larsen</surname><given-names>CP</given-names></name><name><surname>Troxell</surname><given-names>ML</given-names></name></person-group><article-title>Membranous nephropathy and nonsteroidal anti-inflammatory agents</article-title><source>Am J Kidney Dis</source><year>2013</year><volume>62</volume><issue>5</issue><fpage>1012</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">23773370</pub-id></element-citation></ref><ref id="b10-medscimonit-25-1903"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Increased soluble ST2 and IL-4 serum levels are associated with disease severity in patients with membranous nephropathy</article-title><source>Mol Med Rep</source><year>2017</year><volume>17</volume><issue>2</issue><fpage>2778</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">29207152</pub-id></element-citation></ref><ref id="b11-medscimonit-25-1903"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>A higher frequency of IL-10-producing B cells in Hepatitis B virus associated membranous nephropathy</article-title><source>Clin Exp Pharmacol Physiol</source><year>2016</year><volume>43</volume><issue>4</issue><fpage>417</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">26825579</pub-id></element-citation></ref><ref id="b12-medscimonit-25-1903"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagasawa</surname><given-names>Y</given-names></name><name><surname>Okuzaki</surname><given-names>D</given-names></name><name><surname>Muso</surname><given-names>E</given-names></name><etal/></person-group><article-title>IFI27 is a useful genetic marker for diagnosis of immunoglobulin a nephropathy and membranous nephropathy using peripheral blood</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>4</issue><fpage>e0153252</fpage><pub-id pub-id-type="pmid">27100186</pub-id></element-citation></ref><ref id="b13-medscimonit-25-1903"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><etal/></person-group><article-title>MiR-217 is a useful diagnostic biomarker and regulates human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy</article-title><source>Biomed Res Int</source><year>2017</year><issue>2</issue><fpage>2168767</fpage><pub-id pub-id-type="pmid">29214160</pub-id></element-citation></ref><ref id="b14-medscimonit-25-1903"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>LN</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis</article-title><source>Cell Death Dis</source><year>2018</year><volume>9</volume><issue>5</issue><fpage>533</fpage><pub-id pub-id-type="pmid">29748623</pub-id></element-citation></ref><ref id="b15-medscimonit-25-1903"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Integrated profiling of microRNA expression in membranous nephropathy using high-throughput sequencing technology</article-title><source>Int J Mol Med</source><year>2014</year><volume>33</volume><issue>1</issue><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">24220188</pub-id></element-citation></ref><ref id="b16-medscimonit-25-1903"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Bu</surname><given-names>R</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Profiling and initial validation of urinary microRNAs as biomarkers in IgA nephropathy</article-title><source>Peer J</source><year>2015</year><volume>3</volume><fpage>e990</fpage><pub-id pub-id-type="pmid">26056621</pub-id></element-citation></ref><ref id="b17-medscimonit-25-1903"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Exploration, normalization, and summaries of high density oligonucleotide array probe level data</article-title><source>Biostatistics</source><year>2003</year><volume>4</volume><issue>2</issue><fpage>249</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">12925520</pub-id></element-citation></ref><ref id="b18-medscimonit-25-1903"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><etal/></person-group><article-title>LIMMA powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>7</issue><fpage>e47</fpage><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="b19-medscimonit-25-1903"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><etal/></person-group><article-title>RNA-seq analyses of multiple meristems of soybean: Novel and alternative transcripts, evolutionary and functional implications</article-title><source>BMC Plant Biol</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>169</fpage><pub-id pub-id-type="pmid">24939556</pub-id></element-citation></ref><ref id="b20-medscimonit-25-1903"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Franceschini</surname><given-names>A</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><etal/></person-group><article-title>The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>database issue</issue><fpage>D561</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">21045058</pub-id></element-citation></ref><ref id="b21-medscimonit-25-1903"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><etal/></person-group><article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><issue>11</issue><fpage>2498</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="b22-medscimonit-25-1903"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>GD</given-names></name><name><surname>Hogue</surname><given-names>CW</given-names></name></person-group><article-title>An automated method for finding molecular complexes in large protein interaction networks</article-title><source>BMC Bioinformatics</source><year>2003</year><volume>4</volume><issue>1</issue><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">12513700</pub-id></element-citation></ref><ref id="b23-medscimonit-25-1903"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>MiRDB: An online resource for microRNA target prediction and functional annotations</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>database issue</issue><fpage>146</fpage><lpage>52</lpage></element-citation></ref><ref id="b24-medscimonit-25-1903"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Gene Ontology: Tool for the unification of biology</article-title><year>2000</year><volume>25</volume><issue>1</issue><fpage>25</fpage><lpage>29</lpage></element-citation></ref><ref id="b25-medscimonit-25-1903"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><issue>1</issue><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="b26-medscimonit-25-1903"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nat Protoc</source><year>2008</year><volume>4</volume><issue>1</issue><fpage>44</fpage><lpage>57</lpage></element-citation></ref><ref id="b27-medscimonit-25-1903"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>VG</given-names></name><name><surname>Gon&#231;alves</surname><given-names>GL</given-names></name><name><surname>Costa-Pessoa</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/PKC-&#948;/p38 MAPK pathway activation and trough increased Na+/H+ exchanger isoform 1 activity</article-title><source>BMC Nephrol</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>179</fpage><pub-id pub-id-type="pmid">30005635</pub-id></element-citation></ref><ref id="b28-medscimonit-25-1903"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>RM</given-names></name><name><surname>Wang</surname><given-names>ZB</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Swiprosin-1 promotes mitochondria-dependent apoptosis of glomerular podocytes via P38 MAPK pathway in early-stage diabetic nephropathy</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>45</volume><issue>3</issue><fpage>899</fpage><lpage>916</lpage><pub-id pub-id-type="pmid">29421811</pub-id></element-citation></ref><ref id="b29-medscimonit-25-1903"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname><given-names>K</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Isono</surname><given-names>M</given-names></name><etal/></person-group><article-title>Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells</article-title><source>Am J Physiol Renal Physiol</source><year>2003</year><volume>284</volume><issue>5</issue><fpage>F1037</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12517735</pub-id></element-citation></ref><ref id="b30-medscimonit-25-1903"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Haij</surname><given-names>S</given-names></name><name><surname>Bakker</surname><given-names>AC</given-names></name><name><surname>van der Geest</surname><given-names>RN</given-names></name><etal/></person-group><article-title>NF-kappaB mediated IL-6 production by renal epithelial cells is regulated by c-jun NH2-terminal kinase</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><issue>6</issue><fpage>1603</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15843470</pub-id></element-citation></ref><ref id="b31-medscimonit-25-1903"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Astragaloside IV attenuates complement membranous attack complex induced podocyte injury through the MAPK pathway</article-title><source>Phytother Res</source><year>2012</year><volume>26</volume><issue>6</issue><fpage>892</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">22086717</pub-id></element-citation></ref><ref id="b32-medscimonit-25-1903"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malik</surname><given-names>S</given-names></name><name><surname>Suchal</surname><given-names>K</given-names></name><name><surname>Khan</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK/NF-&#954;B/TNF-&#945; and TGF-&#946;1/MAPK/fibronectin pathways</article-title><source>Am J Physiol Renal Physiol</source><year>2017</year><volume>313</volume><issue>2</issue><fpage>F414</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">28566504</pub-id></element-citation></ref><ref id="b33-medscimonit-25-1903"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomar</surname><given-names>A</given-names></name><name><surname>Vasisth</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Galangin ameliorates cisplatin induced nephrotoxicity <italic>in vivo</italic> by modulation of oxidative stress, apoptosis and inflammation through interplay of MAPK signaling cascade</article-title><source>Phytomedicine</source><year>2017</year><volume>34</volume><fpage>154</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">28899498</pub-id></element-citation></ref><ref id="b34-medscimonit-25-1903"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><etal/></person-group><article-title>PPM1A functions as an ERK phosphatase</article-title><source>FEBS J</source><year>2013</year><volume>280</volume><issue>11</issue><fpage>2700</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">23560844</pub-id></element-citation></ref><ref id="b35-medscimonit-25-1903"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>W</given-names></name></person-group><article-title>PPM1A and PPM1B act as IKK&#946; phosphatases to terminate TNF&#945;-induced IKK&#946;-NF-&#954;B activation</article-title><source>Cell Signal</source><year>2009</year><volume>21</volume><issue>1</issue><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">18930133</pub-id></element-citation></ref><ref id="b36-medscimonit-25-1903"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SR</given-names></name><name><surname>Schaaf</surname><given-names>K</given-names></name><name><surname>Rajabalee</surname><given-names>N</given-names></name><etal/></person-group><article-title>The phosphatase PPM1A controls monocyte-to-macrophage differentiation</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>902</fpage><pub-id pub-id-type="pmid">29343725</pub-id></element-citation></ref><ref id="b37-medscimonit-25-1903"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group><article-title>Crosstalk between MAPK/ERK and PI3K/AKT signal pathways during brain ischemia/reperfusion</article-title><source>ASN Neuro</source><year>2015</year><volume>7</volume><issue>5</issue><comment>pii: 1759091415602463</comment></element-citation></ref><ref id="b38-medscimonit-25-1903"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santamar&#237;a</surname><given-names>D</given-names></name><name><surname>Barri&#232;re</surname><given-names>C</given-names></name><name><surname>Cerqueira</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cdk1 is sufficient to drive the mammalian cell cycle</article-title><source>Nature</source><year>2007</year><volume>448</volume><issue>7155</issue><fpage>811</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17700700</pub-id></element-citation></ref><ref id="b39-medscimonit-25-1903"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>RH</given-names></name><name><surname>Davies</surname><given-names>LC</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name><etal/></person-group><article-title>miR-192 induces G2/M growth arrest in aristolochic acid nephropathy</article-title><source>Am J Pathol</source><year>2014</year><volume>184</volume><issue>4</issue><fpage>996</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">24508230</pub-id></element-citation></ref><ref id="b40-medscimonit-25-1903"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group><article-title>MiR-184 and miR-150 promote renal glomerular mesangial cell aging by targeting Rab1a and Rab31</article-title><source>Exp Cell Res</source><year>2015</year><volume>336</volume><issue>2</issue><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">26165933</pub-id></element-citation></ref><ref id="b41-medscimonit-25-1903"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>WG</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><etal/></person-group><article-title>Downregulation of miR-186 contributes to podocytes apoptosis in membranous nephropathy</article-title><source>Biomed Pharmacother</source><year>2015</year><volume>75</volume><fpage>179</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">26382839</pub-id></element-citation></ref><ref id="b42-medscimonit-25-1903"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><etal/></person-group><article-title>The relationship between amniotic fluid miRNAs and congenital obstructive nephropathy</article-title><source>Am J Transl Res</source><year>2017</year><volume>9</volume><issue>4</issue><fpage>1754</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">28469780</pub-id></element-citation></ref><ref id="b43-medscimonit-25-1903"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Wang</surname><given-names>XX</given-names></name><name><surname>Yao</surname><given-names>XM</given-names></name><etal/></person-group><article-title>MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency</article-title><source>Am J Nephrol</source><year>2011</year><volume>34</volume><issue>6</issue><fpage>549</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">22123611</pub-id></element-citation></ref><ref id="b44-medscimonit-25-1903"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YQ</given-names></name><name><surname>Wang</surname><given-names>XX</given-names></name><name><surname>Yao</surname><given-names>XM</given-names></name><etal/></person-group><article-title>Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice</article-title><source>J Nephrol</source><year>2012</year><volume>25</volume><issue>4</issue><fpage>566</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">21983986</pub-id></element-citation></ref><ref id="b45-medscimonit-25-1903"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>YF</given-names></name><name><surname>Wen</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Urinary microRNA-30c-5p and microRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury</article-title><source>Exp Biol Med</source><year>2017</year><volume>242</volume><issue>6</issue><fpage>657</fpage><lpage>67</lpage></element-citation></ref><ref id="b46-medscimonit-25-1903"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>S</given-names></name><etal/></person-group><article-title>Implications of dynamic changes in miR-192 expression in ischemic acute kidney injury</article-title><source>Int Urol Nephrol</source><year>2017</year><volume>49</volume><issue>3</issue><fpage>541</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">28035621</pub-id></element-citation></ref><ref id="b47-medscimonit-25-1903"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>P53 activates miR-192-5p to mediate vancomycin induced AKI</article-title><source>Sci Rep</source><year>2016</year><volume>6</volume><fpage>38868</fpage><pub-id pub-id-type="pmid">27941921</pub-id></element-citation></ref><ref id="b48-medscimonit-25-1903"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LZP</given-names></name><name><surname>Bai</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>L</given-names></name><etal/></person-group><article-title>P53 upregulated by HIF-1&#945; promotes hypoxia-induced G2/M arrest and renal fibrosis <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>J Mol Cell Biol</source><year>2018</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="b49-medscimonit-25-1903"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Cheng</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group><article-title>MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>6</issue><fpage>e99802</fpage><pub-id pub-id-type="pmid">24919189</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-25-1903" position="float"><label>Figure 1</label><caption><p>The hierarchical clustering heat maps of (<bold>A</bold>) differentially expressed genes (DEGs) and (<bold>B</bold>) differentially expressed miRNAs (DEMs) between membranous nephropathy (MN) patients and controls. MN patients and controls were completely separated by DEGs or DEMs.</p></caption><graphic xlink:href="medscimonit-25-1903-g001"/></fig><fig id="f2-medscimonit-25-1903" position="float"><label>Figure 2</label><caption><p>The protein-protein interaction network constructed by the differentially expressed genes. Red represents upregulated genes and green represents downregulated genes.</p></caption><graphic xlink:href="medscimonit-25-1903-g002"/></fig><fig id="f3-medscimonit-25-1903" position="float"><label>Figure 3</label><caption><p>Ranking of nodes in protein-protein interaction (PPI) network to screen hub proteins.</p></caption><graphic xlink:href="medscimonit-25-1903-g003"/></fig><fig id="f4-medscimonit-25-1903" position="float"><label>Figure 4</label><caption><p>(<bold>A&#8211;C</bold>) Modules extracted from protein-protein interaction (PPI) network. Red represents upregulated genes and green represents downregulated genes.</p></caption><graphic xlink:href="medscimonit-25-1903-g004"/></fig><fig id="f5-medscimonit-25-1903" position="float"><label>Figure 5</label><caption><p>The microRNA (miRNA)-target gene regulatory networks. Ellipse represents genes and rhombus represents miRNAs.</p></caption><graphic xlink:href="medscimonit-25-1903-g005"/></fig><table-wrap id="t1-medscimonit-25-1903" position="float"><label>Table 1</label><caption><p>Differentially expressed genes and miRNAs between membranous nephropathy patients and controls.</p></caption><table-wrap-foot><fn id="tfn1-medscimonit-25-1903"><p>FC &#8211; fold change, miRNA &#8211; microRNA.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-medscimonit-25-1903" position="float"><label>Table 2</label><caption><p>GO and KEGG pathway enrichment for differentially expressed genes.</p></caption><table-wrap-foot><fn id="tfn2-medscimonit-25-1903"><p>GO &#8211; gene ontology; KEGG &#8211; Kyoto Encyclopedia of Genes Genomes. Top 10 were listed.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-medscimonit-25-1903" position="float"><label>Table 3</label><caption><p>GO and KEGG pathway enrichment for genes in modules.</p></caption><table-wrap-foot><fn id="tfn3-medscimonit-25-1903"><p>GO &#8211; gene ontology; KEGG &#8211; Kyoto Encyclopedia of Genes Genomes.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-medscimonit-25-1903" position="float"><label>Table 4</label><caption><p>GO and KEGG pathways enrichment for target genes of differentially expressed miRNAs.</p></caption><table-wrap-foot><fn id="tfn4-medscimonit-25-1903"><p>GO &#8211; gene ontology; KEGG &#8211; Kyoto Encyclopedia of Genes Genomes; miRNAs &#8211; microRNAs.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-medscimonit-25-1903" position="float"><label>Table 5</label><caption><p>The intersection genes between peripheral blood mononuclear cells and urine sediments and their regulatory miRNAs.</p></caption></table-wrap></floats-group></article>